Core Insights - Resverlogix Corp. has appointed Mr. Bradley Glass to its board of directors, bringing extensive legal and business experience to the company [1][3]. Company Overview - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company focused on developing first-in-class therapies for chronic diseases, particularly in the field of epigenetics [4]. - The company is developing a new class of epigenetic therapies aimed at regulating disease-causing gene expression, with a focus on improving patients' lives affected by serious illnesses such as cardiovascular disease [5]. Strategic Partnerships - Resverlogix has partnered with EVERSANA™ to facilitate the rapid commercialization of its lead candidate, apabetalone, for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States [6].